BridgeBio Oncology Therapeutics, Inc. reported Q4 and full year 2025 financial results with net loss of $38.8 million and $134.0 million, respectively, alongside preliminary clinical data for BBO-8520, BBO-11818, and BBO-10203 showing encouraging safety and efficacy. Cash position of $425.5 million as of December 31, 2025, expected to fund operations into 2028.
Key takeaways
Cash, cash equivalents and marketable securities totaled $425.5 million as of December 31, 2025, expected to fund operations into 2028
Q4 2025 R&D expenses $38.1 million vs $19.5 million Q4 2024; full year $121.2 million vs $73.1 million 2024
Q4 2025 net loss $38.8 million vs $19.7 million Q4 2024; full year $134.0 million vs $74.3 million 2024
BBO-8520 monotherapy in KRAS G12C NSCLC showed 65% ORR and 68% 6-month PFS as of November 15, 2025
BBO-11818 produced confirmed partial response with 56% tumor reduction in PDAC patient
BBO-10203 showed no hyperglycemia with full target engagement and clinical benefit in CRC and HR+ BC patients
Updated clinical data expected in second half of 2026 across all three programs